Stock Events

Stock Events

Novavax

$11.9

777

-$0.64-5.1% Friday 20:00

Statistics

Day High

12.5

Day Low

11.69

52W High

23.86

52W Low

3.53

Volume

5,806,859

Avg. Volume

12,950,326

Mkt Cap

1.67B

P/E Ratio

-2.2

Dividend Yield

-

Dividend

-

Dividends

0%Dividend Yield

10Y Growth

N/A

5Y Growth

N/A

3Y Growth

N/A

1Y Growth

N/A

Earnings

10MayConfirmed

Q3 2022

Q4 2022

Q1 2023

Q2 2023

Q3 2023

Q4 2023

Q1 2024

-3.46

-1.78

-0.11

1.57

Expected EPS

-1.06

Actual EPS

-1.05

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NVAX. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Moderna is a direct competitor in the mRNA vaccine space, particularly for COVID-19, similar to Novavax's efforts in vaccine development.

Pfizer, in collaboration with BioNTech, developed a COVID-19 vaccine that competes directly with Novavax's COVID-19 vaccine.

BioNTech partners with Pfizer for the COVID-19 vaccine, making it a direct competitor to Novavax in the vaccine market.

Johnson & Johnson

Johnson & Johnson developed a single-shot COVID-19 vaccine, competing in the same pandemic response market as Novavax.

AstraZeneca developed a COVID-19 vaccine using a different technology but competes in the same global vaccine market as Novavax.

Sanofi is working on COVID-19 vaccine candidates and influenza vaccines, positioning it as a competitor in the broader vaccine market.

GlaxoSmithKline, with its extensive vaccine portfolio and efforts in COVID-19 vaccine development, competes in the same space as Novavax.

CureVac competes in the mRNA vaccine space, focusing on COVID-19 and other diseases, similar to Novavax's approach.

Dynavax offers adjuvants for vaccines, making it a competitor in the broader vaccine development and enhancement market.

Dynavax Technologies

Dynavax offers adjuvants for vaccines, making it a competitor in the broader vaccine development and enhancement market.

Analyst Ratings

19$Average Price Target

The highest estimate is $29.

From 4 ratings within the last 6 months. This is not an investment recommendation.

Buy

50%

Hold

50%

Sell

0%

About

Health Technology

Biotechnology

Manufacturing

Biological Product (except Diagnostic) Manufacturing

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Show more...

CEO

Stanley Erck

Employees

1543

Country

US

ISIN

US6700024010

WKN

000A2PKMZ

Listings